Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS - Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $92.00 target price on the stock.

Other analysts have also recently issued reports about the stock. The Goldman Sachs Group increased their target price on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a buy rating in a research note on Tuesday, January 9th. UBS Group reduced their target price on Apellis Pharmaceuticals from $89.00 to $85.00 and set a buy rating for the company in a research report on Wednesday. Raymond James upped their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a strong-buy rating in a research note on Thursday, January 11th. Robert W. Baird reiterated an outperform rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Finally, Needham & Company LLC restated a buy rating and issued a $85.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average target price of $76.67.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS traded down $1.60 during trading hours on Wednesday, reaching $42.30. 2,160,435 shares of the company were exchanged, compared to its average volume of 1,579,954. The stock has a market capitalization of $5.13 billion, a P/E ratio of -9.44 and a beta of 0.97. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The business's 50 day simple moving average is $54.30 and its 200-day simple moving average is $57.42.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company had revenue of $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. During the same quarter in the prior year, the company earned ($1.56) EPS. The firm's quarterly revenue was up 284.3% compared to the same quarter last year. On average, equities research analysts expect that Apellis Pharmaceuticals will post -1.27 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 18,681 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total value of $1,068,179.58. Following the sale, the director now directly owns 173,998 shares of the company's stock, valued at $9,949,205.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director A. Sinclair Dunlop sold 18,681 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $57.18, for a total transaction of $1,068,179.58. Following the sale, the director now owns 173,998 shares in the company, valued at $9,949,205.64. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Pascal Deschatelets sold 69,107 shares of the business's stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company's stock, valued at $60,452,799.11. The disclosure for this sale can be found here. Insiders have sold a total of 376,427 shares of company stock valued at $23,169,639 in the last ninety days. 7.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals by 11.6% in the 1st quarter. ProShare Advisors LLC now owns 8,452 shares of the company's stock worth $497,000 after purchasing an additional 881 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Apellis Pharmaceuticals by 1,300.8% during the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company's stock worth $211,000 after acquiring an additional 3,330 shares during the last quarter. Sei Investments Co. grew its position in shares of Apellis Pharmaceuticals by 57.4% during the 1st quarter. Sei Investments Co. now owns 39,864 shares of the company's stock valued at $2,343,000 after acquiring an additional 14,531 shares during the period. Lisanti Capital Growth LLC increased its stake in shares of Apellis Pharmaceuticals by 92.7% in the 1st quarter. Lisanti Capital Growth LLC now owns 89,210 shares of the company's stock worth $5,244,000 after purchasing an additional 42,905 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its stake in shares of Apellis Pharmaceuticals by 8.3% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company's stock worth $511,000 after purchasing an additional 664 shares in the last quarter. Institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).